Gilead Scraps HR-MDS Trial; FDA OKs Verrica's Molluscum Treatment
- July 22nd, 2023
- 473 views
Gilead Sciences, Inc. (Nasdaq: GILD) announced the termination of the Phase 3 ENHANCE study evaluating magrolimab plus azacitidine as a first-line treatment for higher-risk myelodysplastic syndromes (HR-MDS) due to futility based on a planned analysis.
The safety data observed in this study aligns with the established magrolimab profile and the usual adverse events found in this patient population, prompting Gilead's recommendation to discontinue magrolimab treatment for MDS patients.
On Friday, $GILD closed at $80.64, reflecting a gain of $0.70 (+0.88%)
In other news, Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) gained U.S. FDA approval for YCANTH (cantharidin) topical solution to treat molluscum contagiosum (molluscum) in adult and pediatric patients aged 2 years and older.
Molluscum is a highly contagious viral skin infection, mainly affecting children. YCANTH, a drug-device combination product, is expected to be available through healthcare professionals by September 2023.
$VRCA closed at $7.45 on Friday, up $0.28 (+3.83%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026The Work Behind the Game: How Football Teams Prepare to Compete
September 15th, 2026NJCP Operates on a Prep Model Built Around a Full Season
September 14th, 2026Earnings Preview: High Tide, Kestra Medical, and RF Industries in Focus
September 12th, 2026
Member Login